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its dimensions. Each component is matched 
with other component and covers the solu-
tions appropriate for the program and one of 
component was “Access to Effective Infor-
mation at Decision Making Process which 
called Health Information System”. With 
HTP access to health has increased at a large 
extent and as a result of this situation Turkish 
total health expenditures has increased past 
few years and it was 76 billion Turkish Li-
ras (30.4 billion Euros) for year 2011. Total 
pharmaceutical expenditure was 15.6 billion 
Turkish Liras (6.24 billion Euros) which is 
around 20% of Total Health Expenditures 
(THE) of Turkey of same year.
In Turkey, General Directorate of Pharma-
ceuticals and Pharmacy (IEGM) is responsi-
ble for setting all prices for human medicinal 
INTRODUCTION
The international reference pricing system is 
used for setting prices for human medicinal 
products and controlling health care expen-
diture.
The international reference pricing system 
is started to be implemented in Turkey since 
2004. Actually this system has been started, 
as one of the results of the Health Transfor-
mation Programme (HTP) which has started 
in 2002 with the new government in Turkey. 
It has been aiming to solve the problems of 
the health sector which have not been solved 
before, and which grew as they were not sol-
ved therefore which are perceived as never 
changeable. Health Transformation Program-
me (HTP) consists of 8 components, which 
have been formed to cover the sector with all 
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ABSTRACT
OBJECTIVES: General Directorate of Pharmaceuticals and Pharmacy (IEGM) is responsible for setting all prices for 
human medicinal products. The reference pricing system is used for setting these prices. Reference countries are reviewed 
annually and may be subject to certain alterations. There were 5 reference countries in 2009: Spain, Italy, Germany, France 
and Greece. The aim of this study is to show the distribution of reference countries which were used for reference pricing.
METHODS: The price list of pharmaceuticals which was published by IEGM on 15.04.2011 was used for analysis. Distri-
bution of reference countries and prices were evaluated.
RESULTS: Prices of 6,251 generic and 3,703 original products were set according to the price list. 5,283 of generics and 
3,306 of originals were in the positive list for reimbursement. Reference pricing was used for 2,352 generics and 2,281 
originals. Prices of the remaining were set outside of reference pricing. 32 different countries were used for reference pri-
cing. Italy was the most popular country for reference pricing. Even if it was not a reference country, Germany was used in 
some of the pharmaceuticals. The average reimbursement discount rate and price were 24.43% and 249 TL, respectively. 
There were no colerations between price and reimbursement discount rate, or reference country and reimbursement rate.
CONCLUSION: It has been shown that Italy has the highest impact on the pricing of all pharmaceuticals in Turkey. Even if it 
was not a reference country, Germany showed to affect pharmaceuticals more than other countries which were also not used for 
reference pricing. Even if reimbursement discount rates are stated by the Social Security Institution (SGK), there are different 
discount rates for pharmaceuticals. The analysis stated that there were correlation between price, country and discount rates. This 
analysis is first for the literature. Further analysis is necessary in the light of price changes and newly launched pharmaceuticals 
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products. Reference country prices set the 
basis for pricing of medicinal products licen-
sed in Turkey. European Union (EU) Mem-
ber States and Candidate Countries for whom 
membership is guaranteed within a year may 
be selected as reference countries for pricing 
estimates. Reference countries are reviewed 
annually and may be subject to certain al-
terations. There were 5 reference countries 
in 2011: Spain, Italy, Germany, France, and 
Greece [1,2].
For original products, companies may re-
quest up to a maximum of 100% of the re-
ference price. For those products, to which 
there exists no original formulation within 
Turkey or for generic products, companies 
may request up to a maximum of 66% of the 
reference price for the original product offi-
cially issued by IEGM. The Social Security 
Institution (SGK) determines the discount 
rate for government reimbursement. Original 
products must give 11% discount for be listed 
in the positive list for reimbursement. This 
discount rate is for the first year; it shall be 
increased to 23% in following year. Generic 
products must provide 23% discount from the 
first year. On the other hand, there is a global 
budget agreement with pharmaceutical com-
panies. If the global budget for pharmaceu-
ticals is exceeded, the government may take 
the exceeded budget back from all manu-
facturers. In the year 2010, the government 
increased the discount rate to an additional 
9.5% (in total 20.5% and 32.5%) depending 
on the excess global budget. In some cases, 
even pharmaceutical companies give more 
discount rate for be listed in the positive list; 
sometimes government decreases discount 
rates to 4% for exceptional drugs like orphan 
medicinal products [1,2].
The aim of this study is to show the result 
of IEGM`s reference pricing schemes and 
SGK`s discount schemes.
METHOD
The price list of pharmaceutical drugs which 
was published by IEGM on 15.04.2011 and 
the discount rate list which was published 
by SGK on 01.05.2011 were used for the 
analysis. Distribution of reference countri-
es, prices and discount rates were evaluated. 
2.50 was used as the exchange rate of conver-
ting Turkish Liras (TL) to Euros.
RESULTS
Reference price analysis
According to the price list, prices of 6,251 
generic and 3,703 original products were set. 
5,283 of generics and 3,306 of originals were 
in the positive list for reimbursement. Refe-
rence pricing was used for 2,352 generics and 
2,281 originals. Prices of the remaining were 
set outside of reference pricing. Average pri-
ces for generics and originals which are pri-
ced by reference pricing were 54,12 TL and 
248.55 TL, respectively (Table I).
32 different countries were used for reference 
pricing. The most popular country for refe-
rence pricing in all pharmaceuticals and ge-
nerics (24.47%) was Italy. Italy was followed 
by Spain (21.96%), Greece (19.69%), France 
(11.8%), and Portugal (8.7%) (Table II).
Even if it was not a reference country, Ger-
many was used in 3.71% of pharmaceuticals. 
The other 25 countries were used by 13.29%. 
However the ranking was changed only in 
pharmaceuticals with prices above 200 Tur-
kish Liras (TL) or original pharmaceuticals; 
Greece was the most popular country in these 
rankings by 27.85% and 24.25%, respectively. 
Greece was the most popular country for refe-
rence pricing in originals, except those with a 
price under 50 TL. Although, Germany was 
not a reference country, Germany was used in 
5.45% of original pharmaceuticals. Other 25 
countries were used by 11.03% (Table III). 
Percentage of Italy in generics were 30.38%. 
The ranking in generics is same as all pharma-
ceuticals with different percentages (Table IV).
In reference pricing Out reference pricing*
Generics (TL) 54.12 11.77
Originals (TL) 248.,55 20.2
Table I. Average prices (numbers are rounded)
* Price determined with special conditions.
In all pharmaceuticals  
(%)
> 200 TL  
(%)
> 100 TL, ≤ 200 TL 
(%)
> 50 TL, ≤ 100 TL 
(%)
≤ 50 TL  
(%)
Italy 24.47 16.26 31.26 23.08 25.36
Spain 21.96 14.88 22.91 22.24 23.12
Greece 19.69 27.85 15.51 20.40 18.57
France 11.8 12.11 13.13 14.05 11.18
Portugal 8.7 7.44 5.97 7.69 9.56
Germany 3.7 4.67 1.91 3.01 3.92
Others 9.58 16.78 9.31 9.53 8.28
Table II. Ranking of used countries in reference pricing of all pharmaceutical drugs (numbers are rounded)
In original 
pharmaceuticals (%)
> 200 TL  
(%)
> 100 TL, ≤ 200 TL 
(%)
> 50 TL, ≤ 100 TL 
(%)
≤ 50 TL  
(%)
Greece 24.25 31.51 26.79 30.62 19.63
Spain 19.16 15.97 17.70 22.80 20.09
Italy 18.37 12.82 21.05 17.92 19.70
France 11.16 8.82 12.44 7.82 12.62
Portugal 10.59 7.98 6.22 8.47 12.77
Germany 5.45 5.67 3.83 4.89 5.76
Others 11.03 17.23 11.94 7.49 9.42
Table III. Ranking of used countries in reference pricing of original pharmaceuticals (numbers are rounded)
Prices of the most of the pharmaceuticals, 
both generics and originals, are below 50 TL. 
On the other hand, the price of 20.9% of ori-
ginal pharmaceuticals are above 200 TL, 
against 4.3% of generics (Table V). 
Even though pharmaceuticals which are pri-
ced with Greece, have the highest average 
price in originals with 367,35 TL, pharma-
ceuticals which are priced with France, have 
the highest average price in generics with 
65.17 TL (Table VI).
Reimbursement discount 
rate analysis
Discount rates were analysed only for origi-
nals which are covered with government 
reimbursement and priced due the reference 
pricing scheme, as the discount rate of gene-
rics are similar and are fixed with rules. The 
average reimbursement discount rate and pri-
ce were 24.43% and 249 TL, respectively. 
Reimbursement discount rate of 43% of ori-
ginals were between 20.50-32.50 %. The 
average discount rate and price were 21.61% 
and 153.53 TL, respectively (Table VII). In 
addition, discount rates were evaluated for 
different price limits and reference countries. 
In generic 
pharmaceuticals (%)
> 200 TL  
(%)
> 100 TL, ≤ 200 TL 
(%)
> 50 TL, ≤ 100 TL 
(%)
≤ 50 TL  
(%)
Italy 30.38 32.35 41.43 28.52 29.23
Spain 24.68 9.80 28.10 21.65 25.63
Greece 15.28 10.78 4.29 9.52 17.79
France 12.51 27.45 13.81 20.62 10.13
Portugal 6.94 4.90 5.71 6.87 7.21
Germany 2.04 0 0 1.03 2.57
Others 9.17 14.71 6.67 11.68 7.44
Table IV. Ranking of used countries in reference pricing of generic pharmaceuticals (numbers are rounded)
> 200 TL 
(%)
> 100 TL,  
≤ 200 TL (%)
> 50 TL,  
≤ 100 TL (%)
≤ 50 TL 
(%)
Originals 20.9 9 13 56.4
Generics 4.3 8.9 12.3 74.3
Table V. Ranking of originals and generics depending on price limits (numbers 
are rounded)
All (TL) Originals (TL) Generics (TL)
Greece 239.33 367.35 42.49
Spain 108.78 198.45 41.76
France 121.12 183.5 65.17
Portugal 130.78 181.74 58.06
Italy 91.12 149.11 57.38
Germany 107.44 141.14 20.17
Others 30.94 79.96 10.28
Table VI. Average prices list depeding on reference country (numbers are rounded)
Discount rate 
(%)
Percentage of 
pharmaceuticals (%)
Average 
discount (%)
Average 
price (TL)
< 11 1 5.63 163.45
≥ 11, < 20.50 15 11.66 318.45
≥ 20.50, < 32.50 44 21.61 153.53
= 32.50 37 32.50 351.60
> 32.50 3 42.12 222.79
Table VII. List of reimbursement discount rates (numbers are rounded)
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the exceeded budget back from all manu-
facturers. In the year 2010, the government 
increased the discount rate to an additional 
9.5% (in total 20.5% and 32.5%) depending 
on the excess global budget. In some cases, 
even pharmaceutical companies give more 
discount rate for be listed in the positive list; 
sometimes government decreases discount 
rates to 4% for exceptional drugs like orphan 
medicinal products [1,2].
The aim of this study is to show the result 
of IEGM`s reference pricing schemes and 
SGK`s discount schemes.
METHOD
The price list of pharmaceutical drugs which 
was published by IEGM on 15.04.2011 and 
the discount rate list which was published 
by SGK on 01.05.2011 were used for the 
analysis. Distribution of reference countri-
es, prices and discount rates were evaluated. 
2.50 was used as the exchange rate of conver-
ting Turkish Liras (TL) to Euros.
RESULTS
Reference price analysis
According to the price list, prices of 6,251 
generic and 3,703 original products were set. 
5,283 of generics and 3,306 of originals were 
in the positive list for reimbursement. Refe-
rence pricing was used for 2,352 generics and 
2,281 originals. Prices of the remaining were 
set outside of reference pricing. Average pri-
ces for generics and originals which are pri-
ced by reference pricing were 54,12 TL and 
248.55 TL, respectively (Table I).
32 different countries were used for reference 
pricing. The most popular country for refe-
rence pricing in all pharmaceuticals and ge-
nerics (24.47%) was Italy. Italy was followed 
by Spain (21.96%), Greece (19.69%), France 
(11.8%), and Portugal (8.7%) (Table II).
Even if it was not a reference country, Ger-
many was used in 3.71% of pharmaceuticals. 
The other 25 countries were used by 13.29%. 
However the ranking was changed only in 
pharmaceuticals with prices above 200 Tur-
kish Liras (TL) or original pharmaceuticals; 
Greece was the most popular country in these 
rankings by 27.85% and 24.25%, respectively. 
Greece was the most popular country for refe-
rence pricing in originals, except those with a 
price under 50 TL. Although, Germany was 
not a reference country, Germany was used in 
5.45% of original pharmaceuticals. Other 25 
countries were used by 11.03% (Table III). 
Percentage of Italy in generics were 30.38%. 
The ranking in generics is same as all pharma-
ceuticals with different percentages (Table IV).
In reference pricing Out reference pricing*
Generics (TL) 54.12 11.77
Originals (TL) 248.,55 20.2
Table I. Average prices (numbers are rounded)
* Price determined with special conditions.
In all pharmaceuticals  
(%)
> 200 TL  
(%)
> 100 TL, ≤ 200 TL 
(%)
> 50 TL, ≤ 100 TL 
(%)
≤ 50 TL  
(%)
Italy 24.47 16.26 31.26 23.08 25.36
Spain 21.96 14.88 22.91 22.24 23.12
Greece 19.69 27.85 15.51 20.40 18.57
France 11.8 12.11 13.13 14.05 11.18
Portugal 8.7 7.44 5.97 7.69 9.56
Germany 3.7 4.67 1.91 3.01 3.92
Others 9.58 16.78 9.31 9.53 8.28
Table II. Ranking of used countries in reference pricing of all pharmaceutical drugs (numbers are rounded)
In original 
pharmaceuticals (%)
> 200 TL  
(%)
> 100 TL, ≤ 200 TL 
(%)
> 50 TL, ≤ 100 TL 
(%)
≤ 50 TL  
(%)
Greece 24.25 31.51 26.79 30.62 19.63
Spain 19.16 15.97 17.70 22.80 20.09
Italy 18.37 12.82 21.05 17.92 19.70
France 11.16 8.82 12.44 7.82 12.62
Portugal 10.59 7.98 6.22 8.47 12.77
Germany 5.45 5.67 3.83 4.89 5.76
Others 11.03 17.23 11.94 7.49 9.42
Table III. Ranking of used countries in reference pricing of original pharmaceuticals (numbers are rounded)
Prices of the most of the pharmaceuticals, 
both generics and originals, are below 50 TL. 
On the other hand, the price of 20.9% of ori-
ginal pharmaceuticals are above 200 TL, 
against 4.3% of generics (Table V). 
Even though pharmaceuticals which are pri-
ced with Greece, have the highest average 
price in originals with 367,35 TL, pharma-
ceuticals which are priced with France, have 
the highest average price in generics with 
65.17 TL (Table VI).
Reimbursement discount 
rate analysis
Discount rates were analysed only for origi-
nals which are covered with government 
reimbursement and priced due the reference 
pricing scheme, as the discount rate of gene-
rics are similar and are fixed with rules. The 
average reimbursement discount rate and pri-
ce were 24.43% and 249 TL, respectively. 
Reimbursement discount rate of 43% of ori-
ginals were between 20.50-32.50 %. The 
average discount rate and price were 21.61% 
and 153.53 TL, respectively (Table VII). In 
addition, discount rates were evaluated for 
different price limits and reference countries. 
In generic 
pharmaceuticals (%)
> 200 TL  
(%)
> 100 TL, ≤ 200 TL 
(%)
> 50 TL, ≤ 100 TL 
(%)
≤ 50 TL  
(%)
Italy 30.38 32.35 41.43 28.52 29.23
Spain 24.68 9.80 28.10 21.65 25.63
Greece 15.28 10.78 4.29 9.52 17.79
France 12.51 27.45 13.81 20.62 10.13
Portugal 6.94 4.90 5.71 6.87 7.21
Germany 2.04 0 0 1.03 2.57
Others 9.17 14.71 6.67 11.68 7.44
Table IV. Ranking of used countries in reference pricing of generic pharmaceuticals (numbers are rounded)
> 200 TL 
(%)
> 100 TL,  
≤ 200 TL (%)
> 50 TL,  
≤ 100 TL (%)
≤ 50 TL 
(%)
Originals 20.9 9 13 56.4
Generics 4.3 8.9 12.3 74.3
Table V. Ranking of originals and generics depending on price limits (numbers 
are rounded)
All (TL) Originals (TL) Generics (TL)
Greece 239.33 367.35 42.49
Spain 108.78 198.45 41.76
France 121.12 183.5 65.17
Portugal 130.78 181.74 58.06
Italy 91.12 149.11 57.38
Germany 107.44 141.14 20.17
Others 30.94 79.96 10.28
Table VI. Average prices list depeding on reference country (numbers are rounded)
Discount rate 
(%)
Percentage of 
pharmaceuticals (%)
Average 
discount (%)
Average 
price (TL)
< 11 1 5.63 163.45
≥ 11, < 20.50 15 11.66 318.45
≥ 20.50, < 32.50 44 21.61 153.53
= 32.50 37 32.50 351.60
> 32.50 3 42.12 222.79
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It was shown that there were not any correla-
tion between price and reimbursement di-
scount rate, and referenced country and reim-
bursement rate. Average discount rates were 
similar in all price limits and countries. The 
distribution depending on the discount rate 
limits were different in each country (Table 
VIII and Table IX).
CONCLUSION
As a result of the reference pricing, which 
has been applying in Turkey since 2004, 
pharmaceutical prices has decreased at a lar-
ge extent. The aim of this study was to define 
the reference countries which had the most 
impact on Turkey’s pharmaceutical prices.
Generally some countries may have impact 
on prices more than other countries because 
of international reference pricing. Therefore 
pharmaceutical companies may pay more at-
tention to some countries then the others for 
pricing. This is one of the negative effects of 
reference pricing.
It was reported that Germany and France were 
the most two influential countries followed 
by Italy, Spain and Hungary ahead of a group 
of six countries of about equal impact on 
the EU market [3]. On the other hand, thou-
gh the UK market is only 3% of the global 
pharmaceutical market, it is very influential; 
as already noted, around 25% of the world 
market uses UK prices for reference pricing 
[4]. It was stated that to avoid the negative 
effects of reference pricing, a weighted index 
of prices from as many countries as possible 
should be used to determine the prices in or-
Price limit (TL) Percentage of pharmaceuticals (%) Average discount (%) Average price (TL)
< 5 56 23.40 23.46
≥ 50, < 100 13 26.55 71.75
≥ 100, < 150 5 25.10 120.32
≥ 150, < 200 4 25.80 175.33
≥ 200, < 1,000 15 25.56 468.78
≥ 1,000 6 25.36 2581.94
Table VIII. List of reimbursement discount rate in different prices (numbers are rounded)
Referenced 
country
Average 
discount (%)
Percentage in discount rates (%)
< 11 ≥ 11, < 20.50 ≥ 20.50, < 32.50 = 32.50 > 32.50
France 23.19 1 23 37 37 2
Greece 26.96 0 10 37 48 5
Italy 24.19 1 10 54 30 5
Portugal 24.56 2 13 45 37 3
Spain 25.06 0.5 8.5 55 34 2
Table IX. List of reimbursement discount rate in different countries (numbers are rounded)
der to reduce the direct and indirect impact of 
individual countries [5].
Reference pricing schemes may lead to con-
trol the health expenditures and increase the 
cost-effectiveness of pharmaceuticals. It was 
reported that generics and reference prices 
have lead to decrease prices of statins betwe-
en 2003 and 2008, increasing the cost-effecti-
veness of all statins in Spain [6]. In addition, 
it was shown that most of the countries stated 
price of pharmaceuticals before the reimbur-
sement decision in order to perform a cost 
effectiveness analysis [7]. It is know that cost 
effectiveness analysis is the most important 
analysis for reimbursement decisions. In the 
light of these topics, it can be said that pricing 
is the most important parameter for reimbur-
sement decisions.
The EU is considered as being a single market 
for pharmaceuticals, depending on Directive 
89/105/EEC in 1988. International reference 
pricing will be one of the key parameters for 
being a “single market” for EU. Due to this, 
international reference pricing is important 
for Turkey also as an EU candidate.
These data can be valuable for pharmaceuti-
cal companies who wish to launch new phar-
maceuticals in Turkey. It has been shown that 
Italy has the highest impact on the pricing 
of all pharmaceuticals in Turkey. Even if it 
was not a reference country, Germany show-
ed to affect pharmaceuticals more than other 
countries which were also not used for refe-
rence pricing. This current analysis is first for 
the literature. Further analysis is needed in 
the light of price chances and new launched 
pharmaceuticals.
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